The use of extracts of ginkgo dicotyledonous for the preparation of medicines
The invention relates to medicine. The proposed use of Ginkgo extract bipartite to facilitate withdrawal syndrome for the treatment of persons with addictions to alcohol, amphetamines, morphine and its derivatives and opium and opium narcotic drugs. The invention expands the Arsenal of tools specified destination. 8 C.p. f-crystals, 4 tab., 1 Il. The invention relates to the use of extracts of Ginkgo dicotyledonous for preparing a medicinal product intended for the relief of the syndrome in the treatment of persons with addiction to the consumption of substances that causes addiction and/or chronic addictive, such as, in particular, substances as alcohol, amphetamines, tobacco, drugs.To date, it is known that extracts of Ginkgo dicots possess activity against cardio-vascular system (in particular, reduce the adhesion of platelets), Central nervous system (in particular, exhibit neuroprotective properties), or sense organs (in particular, protects the retina of the eye), see, for example, DeFeudis et al., Ginkgo Biloba Extract (Egb 761

for obtaining a medicinal product intended for the relief of the syndrome in the treatment of persons with addiction to the consumption of substances that causes addiction and/or chronic addictive, such as, in particular, substances as alcohol, amphetamines, tobacco, drugs.The invention applies in particular to the use of compounds of General formula (I)
in which X denotes a radical or O-Gsand Gs-OH denotes a mono - or disaccharide, or one of their salts or analogues, and
-O-GsY indicates HE or O-Gsand Z denotes H,
any W denotes a radical or O-Gs, Y denotes a linear or branched alkoxyalkyl and Z represents N; provided that at least one of W, X, Y and Z denotes O-Gs.Under linear or branched alkoxyalkyl in the present description understand alkoxyalkyl, linear or branched carbon chain of which contains from 1 to 6 carbon atoms. Under a derivative or analogue mono - or disaccharides understand such compounds as N-acetylglucosamine, N-acetylglucosamine, galactosamine, mannosamine, N-tazelgettaze etc.O-Gspick up mainly so that GsHE belonged to a group that includes abequose, rhamnose, arabinose, ribose, xylose, 2-deoxyribose, glucose, galactose, mannose, 2-deoxyglucose, fructose, fucose, N-acetylglucosamine, N-acetylglucosamine, galactosamine, mannosamine, sucrose, lactose, maltose, cellobiose and trehalose. Even more preferably pick up On Gs so that Gs-OH belonged to the group that includes glucose and lactose.The invention also relates to the use of glycosylated derivatives of ginkgolides, in particular of ginkgolides a and b, orientirlaydi glycosylated derivatives of ginkgolides or alkoxycarbonyl of ginkgolides (i.e., compounds formed by the reaction of glycosylation conducted at least two groups of ginkgolides or alkoxysilane derivatives) described in the following publication: M. Weber and Vasela A., Helv. Chim. Acta, 80(1997), 2352-2367.Pharmaceutical compositions containing the compounds according to the invention can be solids, such as powders, granules, tablets, gelatin capsules, liposomes or suppositories. Suitable solid carriers can, for example, be calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidine and wax.Pharmaceutical compositions containing the compounds according to the invention can also be in liquid form, for example in the form of solutions, emulsions, suspensions or syrups. Suitable liquid carriers may, for example, be water, organic solvents, such as glycerol, glycols and mixtures thereof in water in different ratios.The use of the drug in accordance with the present invention can be produced locally, orally, parenterally, by injection (intramuscular, subcutaneous, intravenous, and so on) and so on,Predpoll is about 10 g depending on the type of the calling dependence substance.Unless otherwise noted, all used here is the technical and scientific terms have the same meaning, which usually use an ordinary specialist in the field that applies the present invention. Moreover, all publications, patent applications, all patents and all other following links are part of the invention as reference material.Pharmacological study of the products of the invention
1. The study of the effects of extracts of Ginkgo dicotyledonous on alcohol dependence.Conducted two tests: one in relation to the effects of EGb 761, the other in respect of the other effects of Ginkgo extract bipartite - CF 401 which does not contain bilobalide, but contains ginkgolides twice in EGb 761 (6%).1) to Rats for 15 days to introduce alcohol (they are given as a drink 10% ethanol in the first week and then a 12.5% ethanol). Animals injected oral (in feed) 50 or 100 mg/kg EGb 761 daily for five days prior to the termination of the input of the alcohol (starting from the 11th day) and during the next three days.Estimated behavioral symptoms within three days after you stop typing alcohol in three groups of rats (n=6): control groggy group, receiving alcohol with concomitant administration of 100 mg/kg EGb 761 (in the last two groups EGb 761 was used in the conditions described above). The results of the tests are presented in table I.Found that animals treated with EGb 761, the symptoms of the syndrome (7 criteria) is reduced in proportion to the input dose and that animals have also reduced locomotor hyperactivity.2) to Rats for 15 days to introduce alcohol (they are given as a drink 10% ethanol in the first week and then a 12.5% ethanol). They also introduce oral (in feed) 50 mg/kg of the extract CF 401 daily for five days prior to the termination of the input of the alcohol (starting from the 11th day) and in the next three days.Estimated behavioral symptoms within three days after you stop typing alcohol in two groups of rats (n=6): control group, receiving only the alcohol, and in the group treated with alcohol with concomitant administration of 50 mg/kg of the extract CF 401 in the above-described conditions. The test results presented in table III.Found that animals treated with the extract CF 401, the symptoms associated with the syndrome, reduced in comparison with symptoms in intoxicating control stomach is etamine (0.5 mg/kg) causes rat locomotor hyperactivity (measured using actimetry). Eight equal doses of amphetamine, applied every other day, cause a progressive increase in locomotor activity: a phenomenon called "sensitization".Rats (n=8), which was injected amphetamine described above, within 8 days prior to the use of amphetamine, and during the whole period of use of amphetamine were treated orally with EGb 761 at a dose of 100 mg/kg / day and ginkgolide And at a dose of 5 mg/kg / day.Measurements using actimetry was performed within 1 hour after application of amphetamine on the 9th (the first day of use of amphetamine), 13th, 17th, 21st and 25th day. The results are given in the graph in Annex II.Found that behavioral sensitization by amphetamine reduced in animals treated with ginkgolide And at a dose of 5 mg/kg / day. Even higher and quite remarkable effect was observed with EGb 761 at a dose of 100 mg/kg / day.3. The study of the effects of Ginkgo extract bipartite EGb 761 on the withdrawal syndrome after the use of morphine.Rats every 8 hours (three times a day) for 10 days injected subcutaneously with a dose of morphine, causing locomotor hyperactivity (as measured by the method of actimetry). On the 11th day of the rats injected with naloxone (3 mg/kg) and observed for signs of withdrawal within 60 m which are assessed on a 4-point scale.Two groups of rats for 8 rats in each give EGb 761 (50 or 100 mg/kg / day) for 4 days before the introduction of naloxone and two hours before him. Intoksicazionny rats from the control group will receive only injections of morphine before naloxone, and rats from the other absolute control group will receive only naloxon.Statistical analysis among the parties is carried out using the following tests: parametric ANOVA test Barletta to verify the homogeneity of variantdata and test Dunnett for multiple comparisons.The results of quantitative calculations of the various identified behavioural parameters are given in table IV.
Claims
Same patents:
The invention relates to medicine, specifically to the use of certain pyridyl - and pyrimidyl-piperazines, substituted in position 1 of the piperazine ring arylalkyl, aryloxyalkyl or arylthioureas group, is effective in treating diseases caused by the misuse of drugs
The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen
The invention relates to medicine
The treatment for addiction // 2162330
The invention relates to medicine
The invention relates to medicine
The invention relates to medicine, namely to addiction
Drug for the treatment of patients with opium addiction and the method of their treatment // 2147879
The invention relates to pharmacy and medicine and relates to a medicinal product for the treatment of patients with opiate addiction and their treatment
The invention relates to medicine, to compositions containing polar lipid composition on the basis of nicotine in liquid crystals and colloidal dispersions and their predecessors or secondary products, which are in contact with fluid body and/or under the influence of body temperature into liquid crystals, or a mixture of liquid crystals, which acts as a matrix with controlled release of nicotine, suitable for Smoking cessation and/or replacement area
Drug and treatment nikotinizma // 2197268
The invention relates to medicine, in particular, pharmacology, and can be used to treat nikotinizma, including for the treatment of the syndrome of nicotine and psychosomatic consequences of tobacco use
Antinicotine alcohol product // 2157704
The invention relates to medicine, in particular to the prevention and treatment of alcoholism, nicotinamine and addiction in General
For the treatment of tobacco // 2147242
The invention relates to medicine, specifically to medicines from plants
Method of treating tobacco // 2146942
The invention relates to medicine, specifically to therapeutic methods for treating tobacco
For the treatment of tobacco // 2146941
The invention relates to medicine, specifically to medicines on the basis of herbal remedies designed to treat tobacco
The invention relates to means on the basis of natural ingredients with antitoxic action of alcohol poisoning, and can be used both in the medical and food industry
Dosage form naltrexone // 2200556
The invention relates to the field of medicine and relates to dosage forms of medicinal preparations, namely pharmaceutical forms of naltrexone
The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen
The invention relates to new arylpyrimidines compounds of formula I having the effect of antagonist 5HT2B-receptor, and pharmaceutical compositions
The invention relates to medicine